biosimilars

Showing 15 posts of 87 posts found.

Coins

ANALYSIS: The challenges of forecasting biosimilar sales across Europe

October 29, 2015
Manufacturing and Production, Research and Development, Sales and Marketing biologics, biosimilars, generics, patent cliff, patents, sales, sales forecasts

The introduction of biologic medicines revolutionised treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases.The landscape …

BGMA D-G Warwick Smith

OPINION: ‘More work remains if biosimilars are to fulfil their potential’

October 27, 2015
Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents

Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …

Humira

Future Focus: The industry’s top five biggest drug patent expirations in 2016

October 21, 2015
Manufacturing and Production, Research and Development biosimilars, blockbuster, generics, patent cliff, patents

From Humira to Cubicin, some multi-billion dollar drugs are set to be hit hard by patent expiries next year, and …

sandoz_building

FDA accepts Sandoz submission for Amgen biosimilar

October 2, 2015
Medical Communications, Research and Development Amgen, FDA, Novartis, Sandoz, biosimilars

Sandoz, a Novartis company and a global leader in biosimilars, has announced today that the US Food and Drug Administration …

zarxio

Sandoz launches first US biosimilar

September 3, 2015
Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …

Abasaglar

Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

Toujeo pen

Sanofi launches new insulin Toujeo in the UK

August 4, 2015
Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo

Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …

Hospira image

Pfizer to buy Hospira for $17 billion

February 5, 2015
Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger

Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …

screen_shot_2014-02-21_at_10

New head of Biosimilars for Merck KGaA

February 21, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA, biosimilars, simon sturge

Simon Sturge is joining Merck KGaA from Boehringer Ingelheim in order to head its Biosimilars unit. In his new role …

Merck KGaA pushes biosimilars

February 12, 2014
Research and Development, Sales and Marketing Dr Reddy's, Merck KGaA, biosimilars, dr reddys, generics

Merck KGaA is to take big strides into the world of biosimilars, according to the German company’s chairman Karl-Ludwig Kley. …

Biocon image

Herceptin biosimilar set for Indian market

January 21, 2014
Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab

Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …

Hospira image

Hospira’s Inflectra approved in Europe

September 10, 2013
Research and Development, Sales and Marketing Hospira, Janssen, Remicade, biosimilars, inflectra

Hospira has been the first firm to meet the European Commission’s approval for a biosimilar monoclonal antibody therapy with its …

Lonza image

Teva and Lonza abandon biosimilars joint venture

July 26, 2013
Manufacturing and Production, Research and Development CMO, Levin, Lonza, Teva, biosimilars

Escalating costs have led Teva and contract manufacturing organisation (CMO) Lonza to abandon a joint venture set up in 2009 …

EMA image

EMA ponders biosimilar guideline

May 14, 2013
Research and Development, Sales and Marketing EMA, biosimilars

The European Medicines Agency is thinking about changes to its guidance on similar biological medicines and has published a draft …

Biogen and Samsung invest $300m on joint biosimilars venture

December 8, 2011
Manufacturing and Production Biogen, Samsung, biosimilars

Biogen Idec and Samsung will invest $300 million in a joint venture to develop biosimilars. Both firms will contribute a …

Latest content